Fc receptor like 4Genealiases: CD307d · FCRH4 · IGFP2 · IRTA1
Q-omics provides the consensus-scored FCRL4 profile across patient tissues and cancer cell-line models. FCRL4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FCRL4 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, FCRL4 RNA expression shows 11,730 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where FCRL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCRL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCRL4 survival associations across molecular data types. FCRL4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCRL4 RNA expression–survival associations across cancer types. High FCRL4 expression shows unfavorable associations in KIRP, but favorable associations in HNSC, SKCM, LUAD, BLCA and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FCRL4 RNA expression.
This table summarizes FCRL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FCRL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCRL4 shows lower tumor expression in COAD and higher tumor expression in LUAD, BRCA, KIRC, KICH and UCEC. The COAD box plot shows higher FCRL4 RNA expression in normal versus tumor tissue (log2 FC = −0.647, t-test p < 0.001).
This table shows molecular features associated with FCRL4 in patient tissues and cancer cell lines. In patient samples, FCRL4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FCRL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
